AbbVie’s Stalling Tactics On Humira Pay Off – In More Ways Than One
Executive Summary
A US House hearing focused on long-standing criticism of AbbVie for its ability to delay biosimilar competition for Humira. AbbVie was also able to delay the hearing, and that also seemed to work out well for the company.
You may also be interested in...
Biosimilars Adoption In Europe, US: Some Wins, 'Incomplete' Policies
Industry chiefs and experts, including Sandoz' global head of biopharmaceuticals, deliberated at the recent AAM meeting the status of biosimilars adoption in Europe and trends and opportunities to generate savings for both the US federal government and payers.
Biosimilars Adoption In Europe, US: Some Wins, 'Incomplete' Policies
Industry chieftains and experts, including Sandoz biopharma's global head, deliberated at the recent AAM meeting the status of biosimilars adoption in Europe and trends and opportunities to generate savings for both the US federal government and payers.
Generic Industry’s Future May Include A Role In The Gene Therapy Space
Trade association’s CEO says a new strategic planning initiative will consider among other things how gene therapy could fit into the generic industry business model.